127 related articles for article (PubMed ID: 35829780)
1. A prospective multicenter study investigating rituximab combined with intensive chemotherapy in newly diagnosed pediatric patients with aggressive mature B cell non-Hodgkin lymphoma (CCCG-BNHL-2015): a report from the Chinese Children's Cancer Group.
Gao YJ; Fang YJ; Gao J; Yan J; Yang LC; Liu AG; Ju XL; Lu J; Han YL; Wang J; Xie M; Guo X; Tang JY
Ann Hematol; 2022 Sep; 101(9):2035-2043. PubMed ID: 35829780
[TBL] [Abstract][Full Text] [Related]
2. Effect of rituximab on immune status in children with aggressive mature B-cell lymphoma/leukemia-a prospective study from CCCG-BNHL-2015.
Dong J; Xu Z; Guo X; Ye F; Fan C; Gao J; Gao Y; Yang L
Heliyon; 2024 Mar; 10(5):e27305. PubMed ID: 38495131
[TBL] [Abstract][Full Text] [Related]
3. Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial.
Alexander S; Aupérin A; Bomken S; Csóka M; Kazanowska B; Chiang AK; Andres M; Uyttebroeck A; Burke GAA; Zsiros J; Pillon M; Bollard CM; Mussolin L; Verdu-Amoros J; Neven B; Barkauskas DA; Wheatley K; Patte C; Gross TG; Minard-Colin V; ;
Lancet Haematol; 2023 Jun; 10(6):e445-e457. PubMed ID: 37094596
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of the efficacy of CCCG-97 and BFM-90 protocols in the treatment for children with mature B-cell non-Hodgkin's lymphoma].
Meng JH; Gao YJ; Lu FJ; Zhai XW; Wang HS; Li J
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):222-7. PubMed ID: 22780979
[TBL] [Abstract][Full Text] [Related]
5. Rituximab-combined anthracycline-free chemotherapy in newly diagnosed paediatric and adolescent patients with non-high-risk aggressive mature B cell lymphoma: protocol for a single-arm, open-label, multicentre, phase II study (the Japan Children's Cancer Group Multicentre Trial, JPLSG B-NHL-20).
Sekimizu M; Fukano R; Koga Y; Mitsui T; Fujita N; Mori T; Hori D; Tanaka M; Ohki K; Iwafuchi H; Nakazawa A; Mori T; Kobayashi R; Hashimoto H; M Saito A; Kamei M;
BMJ Open; 2024 Mar; 14(3):e080762. PubMed ID: 38508620
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92).
Pillon M; Di Tullio MT; Garaventa A; Cesaro S; Putti MC; Favre C; Lippi A; Surico G; Di Cataldo A; D'Amore E; Zanesco L; Rosolen A
Cancer; 2004 Jul; 101(2):385-94. PubMed ID: 15241838
[TBL] [Abstract][Full Text] [Related]
7. Optimal dosage of rituximab for children with Burkitt lymphoma.
Huang S; Jin L; Yang J; Zhang M; Zhang Y; Peng Y; Duan Y; Zheng H
Ann Hematol; 2024 Mar; 103(3):893-903. PubMed ID: 38091052
[TBL] [Abstract][Full Text] [Related]
8. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.
Minard-Colin V; Aupérin A; Pillon M; Burke GAA; Barkauskas DA; Wheatley K; Delgado RF; Alexander S; Uyttebroeck A; Bollard CM; Zsiros J; Csoka M; Kazanowska B; Chiang AK; Miles RR; Wotherspoon A; Adamson PC; Vassal G; Patte C; Gross TG; ;
N Engl J Med; 2020 Jun; 382(23):2207-2219. PubMed ID: 32492302
[TBL] [Abstract][Full Text] [Related]
9. Improved Outcome of Newly Diagnosed Childhood Mature B-Cell Lymphoma/Leukemia With High Tumor Burden Treated With BFM95-based Protocol Combining Rituximab: A Report From Shanghai, China.
Fu Y; Wang H; Zhai X; Qian X; Meng J; Miao H; Zhu X; Yu Y; Lu F
J Pediatr Hematol Oncol; 2019 Apr; 41(3):170-174. PubMed ID: 30664102
[TBL] [Abstract][Full Text] [Related]
10. Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.
Mori T; Osumi T; Kada A; Ohki K; Koga Y; Fukano R; Fujita N; Mitsui T; Mori T; Saito AM; Nakazawa A; Kobayashi R; Sekimizu M
Eur J Haematol; 2024 Apr; 112(4):585-593. PubMed ID: 38112205
[TBL] [Abstract][Full Text] [Related]
11. [A collaborative study on children with mature B-cell non-Hodgkin's lymphoma in China].
; ; ;
Zhonghua Er Ke Za Zhi; 2014 Sep; 52(9):649-54. PubMed ID: 25476425
[TBL] [Abstract][Full Text] [Related]
12. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
Frontzek F; Ziepert M; Nickelsen M; Altmann B; Glass B; Haenel M; Truemper L; Held G; Bentz M; Borchmann P; Dreyling M; Viardot A; Kroschinsky FP; Metzner B; Staiger AM; Horn H; Ott G; Rosenwald A; Loeffler M; Lenz G; Schmitz N
Lancet Haematol; 2021 Apr; 8(4):e267-e277. PubMed ID: 33667420
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Harting R; Venugopal P; Gregory SA; O'brien T; Bogdanova E
Clin Lymphoma Myeloma; 2007 May; 7(6):406-12. PubMed ID: 17621406
[TBL] [Abstract][Full Text] [Related]
14. Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Osumi T; Mori T; Fujita N; Saito AM; Nakazawa A; Tsurusawa M; Kobayashi R
Pediatr Blood Cancer; 2016 Oct; 63(10):1794-9. PubMed ID: 27314926
[TBL] [Abstract][Full Text] [Related]
15. [Mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 regimen in the treatment of pediatric Burkitt lymphoma].
Zhang M; Wu P; Duan YL; Jin L; Yang J; Huang S; Liu Y; Hu B; Zhai XW; Wang HS; Fu Y; Li F; Yang XM; Liu AS; Qin S; Yuan XJ; Dong YS; Liu W; Zhou JW; Zhang LP; Jia YP; Wang J; Qu LJ; Dai YP; Guan GT; Sun LR; Jiang J; Liu R; Jin RM; Wang ZJ; Wang XG; Zhang BX; Chen KL; Zhuang SQ; Zhang J; Zhou CJ; Gao ZF; Zheng MC; Zhang Y
Zhonghua Er Ke Za Zhi; 2022 Oct; 60(10):1011-1018. PubMed ID: 36207847
[No Abstract] [Full Text] [Related]
16. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
17. Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study.
Samochatova EV; Maschan AA; Shelikhova LN; Myakova NV; Belogurova MB; Khlebnikova OP; Shamardina AV; Ryskal OV; Roumiantseva JV; Konovalov DM; Dubrovina ME; Rumyantsev AG
J Pediatr Hematol Oncol; 2014 Jul; 36(5):395-401. PubMed ID: 23823112
[TBL] [Abstract][Full Text] [Related]
18. [NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphoma in children and adolescents. Part 3: An intermediate term analysis of the B-NHL/B-ALL].
Reiter A; Schrappe M; Yakisan E; Sauter S; Ebell W; Zimmermann M; Hartmann W; Kremens B; Kuhn N; Claviez A
Klin Padiatr; 1994; 206(4):242-52. PubMed ID: 7967420
[TBL] [Abstract][Full Text] [Related]
19. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95.
Woessmann W; Seidemann K; Mann G; Zimmermann M; Burkhardt B; Oschlies I; Ludwig WD; Klingebiel T; Graf N; Gruhn B; Juergens H; Niggli F; Parwaresch R; Gadner H; Riehm H; Schrappe M; Reiter A;
Blood; 2005 Feb; 105(3):948-58. PubMed ID: 15486066
[TBL] [Abstract][Full Text] [Related]
20. A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma.
Papadopoulos KP; Lopez-Jimenez J; Smith SE; Steinberg J; Keating A; Sasse C; Jie F; Thyss A
Leuk Lymphoma; 2016 Aug; 57(8):1848-55. PubMed ID: 26857688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
